FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC
On September 24, the U.S. Food and Drug Administration (FDA) approved the HIF-2α inhibitor belzutifan (Welireg) in combination with the tyrosine kinase inhibitor lenvatinib (Lenvima) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following treatment with a PD-1 or ...
FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test
A multi-cancer early detection test named Galleri from the health-care company GRAIL received a favorable vote from the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration (FDA) Medical Devices Advisory Committee. The Committee voted for approval of the premarket...
New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer
A multimodal artificial intelligence (AI) model incorporating multiscale histopathology features was able to predict recurrence risk in patients with early-stage hormone receptor–positive and HER2-negative breast cancer more accurately than the 21-gene recurrence score, Oncotype DX, according to...
CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing
New updates to the College of American Pathologists’ (CAP) Cancer Protocols will affect breast cancer biomarker reporting and molecular testing for gastrointestinal stromal tumors (GISTs), reflecting advances in precision oncology and laboratory accreditation. The updates are part of revisions to...
Robert A. Kyle, MD, Myeloma Expert, Dies at 98
The International Myeloma Foundation (IMF) shared news of the passing of Robert A. Kyle, MD, at age 98 on September 2, 2026. Dr. Kyle was a highly revered expert in the field of myeloma research and known to many as the “Father of Myeloma” for his groundbreaking work in hematology. Dr. Kyle was...
Tambotatug Pelitecan May Improve Survival Outcomes in Relapsed SCLC
The B7-H3–targeting antibody-drug conjugate tambotatug pelitecan significantly improved overall survival compared with topotecan in patients with small cell lung cancer (SCLC) that had progressed after first-line platinum-based therapy, according to results of the phase III TAISHAN-302 trial...
Daraxonrasib Shows Antitumor Activity in Previously Treated RAS-Mutant NSCLC
Daraxonrasib produced responses in more than 30% of patients with previously treated advanced RAS-mutant non–small cell lung cancer (NSCLC), with activity observed across multiple RAS mutations in a phase I/II study. Results from Kathryn C. Arbour, MD, David S. Hong, MD, and colleagues were...
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma
On September 23, 2026, the U.S. Food and Drug Administration (FDA) approved lirafugratinib (Lyrfigtu) for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other...
SUO/AUA Updates Guidelines for Non–Muscle Invasive Bladder Cancer
The American Urologic Association (AUA), in partnership with the Society of Urologic Oncology (SUO), has released an amendment for 2026 to the Diagnosis and Treatment of Non–Muscle Invasive Bladder Cancer (NMIBC) Guideline, published in The Journal of Urology. The amendment introduces 40 new and...
Excess Mortality Halts Trial of Venetoclax Added to DA-EPOCH-R in Double-Hit Lymphoma
Adding venetoclax to dose-adjusted EPOCH-R (DA-EPOCH-R) did not improve progression-free survival and resulted in excess toxicity and mortality among patients with newly diagnosed double-hit lymphoma, prompting early closure of the double-hit lymphoma cohort of the randomized ALLIANCE A051701...
Germline EGFR T790M Associated With Significant Lung Cancer Risk
Researchers have found a significantly increased risk of lung cancer in individuals with an EGFR T790M germline variant, about 25 times higher than in noncarriers, according to study findings published in Science.
“Today, lung cancer screening is driven almost entirely by smoking history,” said...
Second-Line Investigational Monoclonal Antibody in Metastatic Squamous NSCLC
Patients with metastatic squamous non–small cell lung cancer (NSCLC) whose disease progressed following PD-1/-L1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti–CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving...
Neoadjuvant Anbenitamab/Chemotherapy Combination Improves Response in ERBB2-Positive Breast Cancer
Neoadjuvant treatment with the ERBB2-biparatopic antibody anbenitamab plus a solvent-free albumin-bound docetaxel formulation (HB1801) significantly improved total pathologic complete response vs conventional therapy with trastuzumab plus pertuzumab and a taxane (THP) in patients with early or...
Dual Oral Regimen Shows Encouraging Activity in KRAS G12C–Mutated Metastatic Colorectal Cancer
The first clinical evaluation of the chemotherapy-free combination of ifebemtinib and garsorasib showed antitumor activity in patients with previously treated KRAS G12C–mutated metastatic colorectal cancer, although the improvement in objective response rate over garsorasib alone did not reach...
BRAF Class Alterations in NSCLC Have Different Characteristics, Outcomes, and Co-Mutations, Research Shows
Researchers have identified varying clinicopathologic characteristics and outcomes between patients with non–small cell lung cancer (NSCLC) and class II and III BRAF mutations, according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World...
AACR Releases Annual Cancer Progress Report
The American Association for Cancer Research (AACR) has released the 16th edition of its annual Cancer Progress Report. This comprehensive report provides current data on cancer incidence, mortality, and survivorship. It also outlines how basic, translational, and clinical cancer research and...
KEYNOTE-826: Long-Term Outcomes With Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer
Five-year follow-up from the phase III KEYNOTE-826 trial suggests a durable benefit with first-line pembrolizumab plus platinum-based chemotherapy, with or without bevacizumab, in patients with recurrent or metastatic cervical cancer, according to Hasegawa et al in JAMA Oncology.
At the first...
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
A lower-cost chemoimmunotherapy approach including oral triple metronomic chemotherapy (TMC) combined with ultra-low-dose immunotherapy termed TMC-I could extend survival for patients with advanced head and neck squamous cell carcinoma in resource-limited countries, according to investigators from...
Mobile CT Lung Cancer Screening May Expand Access for Underserved Populations
Mobile low-dose computed tomography (LDCT) screening may be able to reach high-risk and socially vulnerable populations in resource-limited settings, according to initial results from the Third Brazilian Early Lung Cancer Trial (BRELT3) presented at the International Association for the Study of...
ASTRO Issues Its First Clinical Guideline on Radiation Therapy for Bladder Cancer
For appropriately selected patients with muscle-invasive bladder cancer, bladder preservation can be a curative treatment option, according to a new clinical guideline from the American Society for Radiation Oncology (ASTRO). The recommendations support trimodal therapy (maximal transurethral...
Losing Weight and Breast Cancer Risk? The GLP-1 Question
The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity and diabetes has sparked interest in their potential effects on breast cancer risk and outcomes. At the 2026 ASCO Annual Meeting, investigators presented several observational studies examining the relationship...
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
On September 18, the U.S. Food and Drug Administration (FDA) approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio) for adults with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with...
Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer
In the large, platform-based, independent validation study CATALINA, published by Dixon-Douglas et al in The Lancet Oncology, two artificial intelligence (AI)-derived computational tumor-infiltrating lymphocyte (cTIL) models, which were deployed without retraining or modification, provided...
NCCN Releases New Guideline for Patients and Caregivers: Older Adults With Cancer
The National Comprehensive Cancer Network® (NCCN®) has released a new resource to help patients and caregivers understand how to tailor cancer care for aging populations.
“The medical advances we’ve seen in cardiology and infectious disease are a huge triumph; because we are better at treating...
First-Line Amivantamab/Chemotherapy in EGFR Exon 20 Insertion–Positive Advanced NSCLC
Results from the phase III PAPILLON study show that first-line amivantamab plus carboplatin/pemetrexed (amivantamab/chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients with previously untreated advanced non–small cell lung cancer (NSCLC)...
Alcohol-Attributable Cancer Deaths More Than Double in the United States
Cancer mortality associated with alcohol use has risen in the United States, disproportionately affecting males and adults aged at least 55 years, according to a population-based observational trend analysis published by Jani et al in The Lancet Regional Health – Americas.
“Our findings highlight...
Azacitidine/Venetoclax Improves Event-Free Survival in Fit Patients With AML
Azacitidine plus venetoclax significantly prolonged event-free survival compared with intensive induction chemotherapy in previously untreated patients with acute myeloid leukemia (AML) who were eligible for induction therapy. Results of the randomized phase II PARADIGM trial, led by Fathi et al,...
Tumor Budding Grading System Can Identify High-Risk Patients With Lung Squamous Cell Carcinoma
A tumor budding–based grading system was able to successfully identify patients with resected lung squamous cell carcinoma who were at a higher risk of poor overall survival and relapse-free survival outcomes, according to findings presented at the International Association for the Study of Lung...
AI’s Evolving Role in Clinical Care Enterprise-Wide
Artificial intelligence could reshape health care by reducing administrative work, helping physicians identify and manage disease, and extending care beyond traditional clinical settings—potentially allowing caregivers to focus more on patient care and human interaction, according to Cleveland...
FDA Approves Zanidatamab Combination Regimens for HER2-Positive Gastric, GEJ, or Esophageal Cancer
On August 25, 2026, the U.S. Food and Drug Administration (FDA) approved zanidatamab-hrii (Ziihera) for two indications, including:
- in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra), as first-line treatment for adults with HER2-positive...
High-Risk Prostate Cancer: GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
First-Line Trastuzumab Deruxtecan Prolongs PFS in HER2-Mutant NSCLC
Trastuzumab deruxtecan significantly improved progression-free survival over pembrolizumab plus platinum-based chemotherapy for patients with advanced or metastatic HER2-mutant non–small cell lung cancer (NSCLC) who were being treated in the first-line setting, according to phase III DESTINY-Lung04 ...
Zipalertinib Added to Chemotherapy Improves Progression-Free Survival in First-Line EGFR Exon 20 Mutation–Positive NSCLC
The addition of zipalertinib to platinum/pemetrexed chemotherapy led to a significant improvement in progression-free survival in patients with advanced non–small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation, according to phase III findings presented at the International...
FDA Approves New Labeling of ROS1 Inhibitor in TKI-Naive Advanced NSCLC
The U.S. Food and Drug Administration (FDA) has approved updated labeling of taletrectinib (Ibtrozi), an oral, CNS-active, selective next-generation ROS1 inhibitor therapy for non–small cell lung cancer (NSCLC), reflecting a median duration of response of 49.7 months in tyrosine kinase inhibitor...
Zidesamtinib Demonstrates 94% Response Rate in TKI-Naive Patients With Advanced ROS1-Positive NSCLC
New results from the global phase I/II ARROS-1 trial showed clinically meaningful activity with the ROS1 selective inhibitor zidesamtinib in patients with advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI). The...
OPTIMUM Trial Reports 5-Year Outcomes With Extended Therapy in High-Risk Multiple Myeloma
The 5-year follow-up of the phase II OPTIMUM/MUKnine trial found sustained improvements in progression-free and overall survival with an intensive, risk-adapted treatment strategy for patients with newly diagnosed high-risk multiple myeloma. The findings, reported by Kaiser et al in The Lancet...
What Constitutes Clinical Expertise in an AI-Enabled Era?
In a keynote speech delivered recently at Cleveland Clinic's A.I. Summit for Healthcare Professionals, Peter Clardy, MD, of Google for Health, made the case that the rapid evolution currently underway in AI is unfolding as clinicians are also being asked to make decisions from an ever-expanding...
American Cancer Society Urges Men to Understand Their Risk for Prostate Cancer
This September, in honor of Prostate Cancer Awareness Month, the American Cancer Society is encouraging men to discuss their risks of prostate cancer with their doctors and the possibility of screening.
The American Cancer Society noted that cases of prostate cancer have continued to increase by...
Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC
Relapsed small cell lung cancer (SCLC) remains a major therapeutic challenge, with limited treatment options and poor outcomes after disease progression on platinum-based chemotherapy and immunotherapy. At the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on...
ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma
The combination of the epidermal growth factor receptor (EGFR)-directed antibody-drug conjugate (ADC) becotatug vedotin and the PD-1 inhibitor pucotenlimab demonstrated antitumor activity in patients with recurrent or metastatic nasopharyngeal carcinoma previously treated with platinum-based...
Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC
An 8-year update of the phase III ADAURA trial showed that adjuvant osimertinib continued to demonstrate an overall survival benefit over placebo in patients with resected EGFR-mutated non–small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study ...
PD-L1–High Metastatic NSCLC: First-Line Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Progression-Free Survival Endpoint
Sacituzumab govitecan-hziy plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non–small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS)...
Ivonescimab Significantly Improves Overall Survival vs Pembrolizumab in PD-L1–Positive Advanced NSCLC
Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, was compared with pembrolizumab as first-line treatment for patients with PD-L1–positive advanced non–small cell lung cancer (NSCLC). Data from the prespecified interim analysis of the phase III HARMONi-2 trial were presented at the...
Izalontamab Brenitecan Active in Previously Treated EGFR-Positive NSCLC
Izalontamab brenitecan (BL-B01D1), an EGFR x HER3 bispecific antibody, demonstrated antitumor activity and a tolerable safety profile, especially at higher dose levels, in patients with previously treated EGFR-mutated metastatic non–small cell lung cancer (NSCLC). These data from a randomized...
DAROL Examines Darolutamide With Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer
In a post hoc analysis of data from the fourth interim analysis of the DAROL trial, the androgen receptor darolutamide was well tolerated, with no cumulative toxic effects or new safety signals among patients with nonmetastatic castration-resistant prostate cancer receiving concomitant...
MAVERICK Trial Supports Brain MRI Surveillance Alone as Standard of Care for SCLC
Results from the international phase III SWOG S1827 MAVERICK trial show that brain magnetic resonance imaging (MRI) surveillance alone improved cognitive failure-free survival compared with MRI surveillance plus prophylactic cranial irradiation (PCI) in patients with small cell lung cancer (SCLC)....
New Executive Director of the Duke Cancer Institute Named
David Tuveson, MD, PhD, will join Duke Health as Executive Director of the Duke Cancer Institute, effective October 31, 2026.
Dr. Tuveson is currently the Roy J. Zuckerberg Professor of Cancer Research and Director of the National Cancer Institute (NCI)-designated Cancer Center at Cold Spring...
Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC
Adjuvant alectinib was associated with early improvements in health-related quality of life that were maintained over 2 years of treatment in patients with resected ALK-positive non–small cell lung cancer (NSCLC). The new analysis of the phase III ALINA trial, reported by Dziadziuszko et al in The...
Extended-Interval Dosing of Tarlatamab Found Safe, Effective in SCLC
Extended-interval dosing of intravenous tarlatamab, at 20 mg every 3 weeks or 30 mg every 4 weeks, demonstrated efficacy and safety that was consistent with the approved tarlatamab dosing regimen in patients with small cell lung cancer (SCLC), according to findings from the phase II DeLLphi-309...
Favorable Safety Profile Found for Subcutaneous Tarlatamab in ES-SCLC
Subcutaneous administration of tarlatamab was well tolerated in patients with extensive-stage small cell lung cancer (ES-SCLC) in the phase IB DeLLphi-308 trial. Investigators were able to eliminate the preplanned post-dose monitoring in the second part of the study due to the safety of the...
Genomic Profiles Compared in Early- and Average-Onset Metastatic Colorectal Cancer
Early-onset colorectal cancer appears to share much of its genomic landscape with average-onset colorectal cancer, although certain molecular alterations may be enriched among younger patients, according to findings reported by Shin et al in JCO Precision Oncology. The investigators examined...
FDA Approves Topical Photodynamic Therapy for Superficial BCC
Today, the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for aminolevulinic acid hydrochloride topical gel, 10% (Ameluz), in combination with photodynamic therapy (PDT) using the BF-RhodoLED lamp series, for the treatment of superficial basal cell carcinoma...
Perioperative Atezolizumab Plus Chemotherapy Improves Outcomes in Resectable Stage II–IIIB NSCLC
Patients with resectable stage IIB–IIIB non–small cell lung cancer (NSCLC) treated with perioperative atezolizumab plus platinum-based chemotherapy experienced a median event-free survival of 62.8 months compared with 34.9 months for patients receiving chemotherapy alone. However, these results did ...
New NCCN Survey Highlights Persistent Cancer Medication Shortages Across United States
The National Comprehensive Cancer Network® (NCCN®) has published updated data on the current impact of generic cancer medication shortages in the United States. The data come from survey responses from pharmacy directors and other clinical and administrative leadership at NCCN Member Institutions...
NSCLC: FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD) activating...
FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
Today, the U.S. Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft (Besremi) for the treatment of adults with essential thrombocythemia, making it the first new FDA-approved treatment for essential thrombocythemia in nearly 3 decades. Ropeginterferon alfa-2b-njft has been...
FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera
On August 28, the U.S. Food and Drug Administration (FDA) approved rusfertide (Mimrylo) for the treatment of erythrocytosis in adults with polycythemia vera (PV). Rusfertide is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to...
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
On August 26, the U.S. Food and Drug Administration (FDA) approved daraxonrasib (Rasonque), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
...
FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma
On August 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to iberdomide (Zenbexus), a cereblon-modulating protein degrader (CELMoD), in combination with daratumumab and hyaluronidase-fihj plus dexamethasone for adults with multiple myeloma who have received at least one ...
Refined Risk Index Improves Outcome Prediction After Limited-Duration CLL Therapy
A refined dynamic prognostic model incorporating longitudinal measurable residual disease (MRD) assessments may improve prediction of progression-free survival and overall survival in patients with chronic lymphocytic leukemia (CLL) receiving limited-duration therapy. The findings, reported by...
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
In the randomized phase III BRUIN CLL-322 trial, adding fixed-duration pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, to venetoclax-rituximab significantly improved progression-free survival in patients with previously treated chronic lymphocytic leukemia or small lymphocytic ...
Early ctDNA Molecular Response May Predict Outcomes With Azenosertib in Ovarian Cancer
According to the results of a retrospective analysis reported by Jeong et al in JCO Precision Oncology, early molecular response assessed using circulating tumor DNA (ctDNA) was associated with radiographic response and longer time to progression among patients with recurrent high-grade serous...
New Data on 14- vs 28-Day Venetoclax/Azacitidine in AML
New results from Blood Cancer United’s Beat AML Master Clinical Trial published by Borate et al in the journal Blood provide new information about whether older patients with newly diagnosed acute myeloid leukemia (AML) can receive a shorter schedule of venetoclax when it is given in combination...
ESMO Announces 2026 Society Award Recipients
The European Society for Medical Oncology (ESMO) has announced the recipients of the 2026 ESMO Society Awards, recognizing four outstanding oncology professionals whose contributions have advanced cancer research, enhanced clinical care, and strengthened the global oncology community.
ESMO Award...
ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC
In an interim analysis of the phase III ELEVATE trial reported in The New England Journal of Medicine, Yue et al found that patients with completely resected ALK-positive non–small cell lung cancer (NSCLC) who received adjuvant ensartinib experienced significantly longer disease-free survival than...
Prostate Cancer: Higher Saturated Fat Intake May Be Linked to Worse Outcomes
Patients with nonmetastatic prostate cancer who consumed higher quantities of saturated fats, including animal fats, had a higher risk of all-cause mortality, including death from cardiovascular disease and other cancer, according to the results of a study published in JAMA Network Open.
“Our...
Duane A. Mitchell, MD, PhD, Named Director of the UF Health Cancer Institute
The University of Florida has selected Duane A. Mitchell, MD, PhD, as the next Director of the UF Health Cancer Institute.
Dr. Mitchell, the Phyllis Kottler Friedman Professor in the Department of Neurosurgery, assumes the role September 21 at a pivotal moment for the institute, which earned...
Long-Course Chemoradiotherapy Shows Early Organ Preservation Advantage in Rectal Cancer
Long-course chemoradiotherapy resulted in superior 12-month total mesorectal excision–free survival compared with short-course radiotherapy in the STAR-TREC trial. The interim analysis, led by Simon P. Bach, FRCS, and colleagues and published in The Lancet Oncology, included patients pursuing organ ...
AI Applied to Mammograms May Help Identify Common Cardiovascular Conditions
In addition to searching for breast cancer, artificial intelligence (AI) used in mammography reads may help to detect common cardiovascular diseases, according to study findings presented at the ESC Congress 2026.
“Because mammography is already widely used, analyzing the same images for...
Prostate Cancer: Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care
A set of uncontrolled, modifiable cardiovascular risk factors may help identify a subgroup of patients with prostate cancer who could benefit from additional cardiovascular care, according to findings published in JACC: CardioOncology and presented at the ESC Congress 2026.
“The major findings...
Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain
Over the past 75 years, advances in the treatment of major blood cancers have saved more than 25 million years of life in the United States, according to results of an analysis led by researchers at Blood Cancer United and published by Chang et al in Blood Advances. But the gains have not reached...
Cervical Cancer Nonscreening Increased Over Nearly 2 Decades
Cervical cancer remains a preventable cause of morbidity and mortality, particularly among women who are not reached by screening programs. In a research letter published in JAMA Network Open, Sonawane et al emphasized the importance of identifying those who have never been screened and reported...
Predictors of pCR to Neoadjuvant THP Explored in HER2-Positive Breast Cancer
Secondary analyses of the prospective EA1181/CompassHER2 pCR trial identified clinicopathologic and molecular factors associated with pathologic complete response (pCR) after de-escalated neoadjuvant therapy with a taxane plus trastuzumab and pertuzumab (THP) in patients with stage II to IIIA...
Prostate Cancer: NRG-GU005 Defines Trade-Offs Between SBRT and Moderately Hypofractionated IMRT
In the international phase III NRG-GU005 trial, stereotactic body radiotherapy (SBRT) improved bowel-related quality of life vs moderately hypofractionated intensity-modulated radiotherapy (IMRT) in patients with favorable intermediate-risk prostate cancer. However, Ellis et al reported in JAMA...
Hypofractionated Salvage Radiotherapy Evaluated After Prostatectomy for Biochemical Recurrence
According to interim results of the phase III SHARE trial reported by Song et al in the Journal of Clinical Oncology, hypofractionated salvage radiotherapy produced similar 4-year oncologic outcomes to conventional radiotherapy among patients with biochemical recurrence after radical prostatectomy, ...
Researchers Define Molecular, Prognostic Subgroups in Therapy-Related Myeloid Neoplasms
Identifying germline genetic variants in patients with therapy-related myeloid neoplasms revealed distinct molecular and prognostic subgroups with distinct outcomes, according to research findings published in Blood Advances. The findings could help to guide physicians in determining which patients ...
ACS Publishes Report on Cancers in Asian American, Native Hawaiian, and Pacific Islander People
Cancer data for Asian American and Native Hawaiian and Pacific Islander (NHPI) people are usually combined, hiding vast differences in cancer risk. New disaggregated data analyzed by researchers at the American Cancer Society (ACS) show that Native Hawaiian women have a 27% higher breast cancer...
MD Anderson President Announces Retirement, Shares Leadership Transition Plans
The University of Texas (UT) MD Anderson Cancer Center is recognizing the leadership of President Peter WT Pisters, MD, following his announced plan to retire from MD Anderson to focus on the next chapter of his career. The UT System Board of Regents and Chancellor John M. Zerwas, MD, have named...
Spartalizumab-Based Triplet Improves Long-Term Overall Survival in BRAF V600–Mutant Melanoma
The addition of spartalizumab to dabrafenib and trametinib demonstrated a long-term survival benefit in patients with BRAF V600–mutant metastatic melanoma, according to the final overall survival analysis from the phase III COMBI-I trial published in the Journal of Clinical Oncology.
“[T]he...
Sociological Study Explores the Concept of ‘Temporal Misalignment’ Among Patients With Terminal Cancer
Scientists are making progress in developing new cancer treatments, but a patient’s experience with cancer is shaped by more than medicine. A new sociological study has found that conflicting medical, work, and family timelines compound inequality, draining resources and displacing goals for even...
Radiation to the Thymus in NSCLC Treatment May Increase Risk of Metastasis
Radiation to the thymus was found to be associated with worse outcomes in patients with non–small cell lung cancer (NSCLC), leading to an increased risk of metastasis, according to findings published in the Annals of Oncology.
“The thymus is currently not routinely treated as an important organ...
Osimertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in EGFR/TP53-Mutated NSCLC
Adding chemotherapy to first-line osimertinib more than doubled median progression-free survival in patients with advanced EGFR-mutated non–small cell lung cancer (NSCLC) harboring concurrent TP53 mutations. The findings come from a phase III randomized trial led by Zhou et al and published in
Two Studies Build Evidence Supporting the Use of ctDNA as an Early Endpoint
Investigators from Friends of Cancer Research (Friends) recently published two manuscripts supporting the use of circulating tumor DNA (ctDNA) as an early endpoint for regulatory decision-making.
The first article, published by Andrews et al in the Journal of Liquid Biopsy, aggregated data from...
Researchers Identify Donor NK Cell Subset That Impairs CAR NK Cell Therapy
Researchers from the University of Texas MD Anderson Cancer Center have discovered a mechanism of donor subset–driven chimeric antigen receptor (CAR) natural killer (NK) dysfunction and have developed a manufacturing strategy for improving the antitumor potency of CAR NK cell therapies for patients ...
Biomarker Guides Treatment Sequencing, Predicts Outcomes in BRAF-Mutated Metastatic Melanoma
Using a blood test to track thymidine kinase activity may help determine optimal first-line treatment for patients with BRAF V600–mutated metastatic melanoma, according to findings published in Clinical Cancer Research.
"The results suggest that thymidine kinase activity may help identify which...
High-Dose Vitamin D3 Does Not Improve PFS in Metastatic Colorectal Cancer
Adding high-dose vitamin D3 to standard chemotherapy plus bevacizumab did not improve progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer (mCRC), according to results from the phase III SOLARIS trial led by Kimmie Ng, MD, MPH, and colleagues and...
Large Multicenter Study Evaluates LITT for Primary and Metastatic Brain Tumors
According to findings from the prospective multicenter LAANTERN study reported by Leuthardt et al in the Journal of Clinical Oncology, laser interstitial thermal therapy (LITT) may offer a minimally invasive cytoreductive option for selected patients with primary and metastatic brain tumors, with...
Tissue-Free ctDNA Assay May Help Identify Recurrence Risk in Early Triple-Negative Breast Cancer
A tissue-free circulating tumor DNA (ctDNA) assay was strongly prognostic for recurrence in patients treated for triple-negative breast cancer and provided a lead time to recurrence comparable to that of a multivariant tumor-informed assay, according to findings from a prognostic study published by ...
Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer
Researchers have reported that a chemotherapy-free combination of four targeted therapies showed encouraging results in patients with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer, offering a potential first-line treatment option that may be more convenient for some...
In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles
A comparative study of the cancer clinical trial portfolios supported by federal funding vs industry funding reveals they have distinct, interdependent roles in cancer research. The findings were published by Unger et al in JAMA Oncology.
The analysis found that, whereas industry trials were more...
Cleveland Clinic to Host Second Annual AI Summit for Health-Care Professionals
AI is one of the most transformative technological advancements of our time, poised to revolutionize every aspect of our lives, including health care. On August 28, 2026, Cleveland Clinic in collaboration with the College of Healthcare Information Management Executives (CHIME), will host the Second ...
Cleveland Clinic President Discusses Friday’s AI Summit for Health-Care Professionals
Artificial intelligence (AI) is one of the most transformative technological advancements of our time, poised to revolutionize every aspect of our lives, including health care.
On August 28, Cleveland Clinic, in collaboration with the College of Healthcare Information Management Executives...
ASTRO Updates Guideline on Radiation Therapy for Pancreatic Cancer
An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of radiation therapy to treat adult patients with pancreatic cancer. The guideline updates ASTRO’s 2019 recommendations to reflect recent clinical trials that...
WashU Medicine Appoints New Chief of Head and Neck Surgery
Andrés M. Bur, MD, FACS, has been named Chief of the Division of Head and Neck Surgery in the Department of Otolaryngology–Head & Neck Surgery at WashU Medicine and Co-Director of the Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, based at Barnes-Jewish...
Colorectal Cancer May Cause Peripheral Neuropathy Before Treatment, Preclinical Study Finds
Colorectal cancer may result in tumor-related inflammation that damages peripheral nerves before even starting cancer treatment, according to preclinical findings published in Nature Communications. This damage may be the reason why colorectal cancer survivors are more likely to develop peripheral...
Expanded EHR Data May Improve Prediction of Early Adverse Events After AML Induction Chemotherapy
Patients with acute myeloid leukemia (AML) frequently experienced unplanned hospital readmission or death within 30 days after discharge following induction chemotherapy, according to findings reported by Chae et al in JCO Clinical Cancer Informatics. The investigators found that incorporating...
Research Finds Supercentenarians Have an Abundance of Cancer-Killing Immune Cells
The human immune system has specialized cells called CD4 cytotoxic T lymphocytes (CD4 CTLs), which have been shown to kill tumor cells in some cancers. These cells multiply in a process called clonal expansion to help fight infection. In a study published by Hashimoto in Cell Reports, researchers...
Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer
Metabolic abnormalities were frequently documented during the first year after men with prostate cancer began concurrent androgen-deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI), according to a large retrospective cohort study led by Amy L. Shaver, PhD, PharmD, MPH, and...
Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds
Adults who have survived Hodgkin lymphoma for at least 5 years may face significantly elevated long-term health risks and cancer and noncancer mortality, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center. The retrospective population-based study,...
Preoperative Weight-Loss Program Shows Feasibility Before Endometrial Cancer Surgery
A short-term, intensive weight-loss program before surgery was feasible and produced meaningful weight loss in women with endometrial cancer and excess weight in the randomized ENDO-CARE trial. The intervention was also associated with fewer postoperative complications, although the study was not...
